Extension Study Evaluating The Safety And Tolerability Of Flexible Doses Of Oral Ziprasidone In Children And Adolescents With Bipolar I Disorder



Status:Recruiting
Conditions:Psychiatric, Bipolar Disorder
Therapuetic Areas:Psychiatry / Psychology
Healthy:No
Age Range:10 - 17
Updated:3/31/2019
Start Date:December 21, 2018
End Date:September 17, 2020
Contact:Pfizer CT.gov Call Center
Email:ClinicalTrials.gov_Inquiries@pfizer.com
Phone:1-800-718-1021

Use our guide to learn which trials are right for you!

26-WEEK OPEN-LABEL EXTENSION STUDY EVALUATING THE SAFETY AND TOLERABILITY OF FLEXIBLE DOSES OF ORAL ZIPRASIDONE IN CHILDREN AND ADOLESCENTS WITH BIPOLAR I DISORDER (MOST RECENT EPISODE MANIC)

This 26-week open-label extension study is designed to provide information on the safety and
tolerability of oral ziprasidone (20-80 mg BID (twice daily) with meals) during long-term
administration in children and adolescents with Bipolar I Disorder (current or most recent
episode manic).

Study A1281201 is a 6 month, open label extension study of the ongoing double blind,
randomized, placebo controlled study of ziprasidone in pediatric Bipolar Disorder (Study
A1281198). Study A1281201 will enroll adolescents aged 10 to 17 years with Bipolar I Disorder
who have participated in double blind Study A1281198. In order to be enrolled in this open
label extension trial, subjects must have met the enrollment criteria for Study A1281198, and
must meet the inclusion and exclusion criteria for Study A1281201 at the extension study
Baseline visit (last visit in the double blind study).

The purpose of adding this extension study to the ongoing Geodon pediatric bipolar program is
to obtain additional longer term safety data in children and adolescents with Bipolar I
disorder treated with ziprasidone.

Inclusion Criteria

- Evidence of personally signed and dated informed consent document by the legal
representative and an assent document by the subject .

- Subjects and their legal guardians who are willing and able to comply with scheduled
visits, treatment plan, laboratory tests, and other study procedures.

- The subjects must have received investigational product in Study A1281198 and
completed at least 3 weeks of double blind treatment before entering this open label
extension.

- In the investigator's opinion, the subject must be likely to benefit from
antipsychotic therapy .

- All fertile male subjects and female subjects of childbearing potential who are
sexually active and/or their legal guardians, as appropriate, must agree that a highly
effective method of contraception

Exclusion Criteria

- Any subjects from the preceding double blind trail who experienced a serious adverse
event which required study medication to be discontinued and the subject to be
withdrawn from the study. Subjects who experienced cardiac arrhythmias, conduction
abnormalities, or QTc prolongation (confirmed and persistent Fridericia's correction
(QTcF) >480 msec or increase from baseline QTcF >60 msec) during the preceding study.

- Subjects requiring any medications not allowed by the Concomitant Medication Table 12
(see "Concomitant Treatment(s)").

- Subjects who require treatment with drugs that are known to consistently prolong the
QT interval (see Concomitant Medication Table 12).

- Subjects who are judged by the investigator as being at imminent risk of suicide.

- Subjects living in the same home as another study participant or having the same
caregiver during the same enrollment period (Such subjects can be enrolled in the
study at different times but may not be in the study at the same time).

- Subjects should be excluded or a risk assessment should be done to verify that it is
safe for the subject to participate in the trial if the subject's responses on the C
SSRS or other information based on the investigator's judgment indicate:

- Suicide ideation associated with actual intent and a method or plan such that a
positive response ('Yes') is made on items 4 or 5 of the suicidal ideation
subscale of the C SSRS; or

- Any suicide behaviors such that a determination of 'yes' is made to any of the
suicide behavior items of the C SSRS.

- Pregnant female subjects, breastfeeding female subjects.

- Participation in other studies other than the preceding Study.

- Other acute or chronic medical or psychiatric condition including recent (within the
past year) or active suicidal ideation or behavior or laboratory abnormality that may
increase the risk associated with study participation or investigational product
administration or may interfere with the interpretation of study results and, in the
judgment of the investigator, would make the subject inappropriate for entry into this
study.
We found this trial at
18
sites
Gainesville, Florida 32607
?
mi
from
Gainesville, FL
Click here to add this to my saved trials
2150 Peachford Road
Atlanta, Georgia 30338
?
mi
from
Atlanta, GA
Click here to add this to my saved trials
Boca Raton, Florida 33487
?
mi
from
Boca Raton, FL
Click here to add this to my saved trials
2291 Westwood Northern Boulevard
Cincinnati, Ohio 45267
?
mi
from
Cincinnati, OH
Click here to add this to my saved trials
?
mi
from
Columbus, OH
Click here to add this to my saved trials
Dothan, Alabama 36303
?
mi
from
Dothan, AL
Click here to add this to my saved trials
830 6th Street South
Everett, Washington 98201
?
mi
from
Everett, WA
Click here to add this to my saved trials
Fayetteville, Georgia 30214
?
mi
from
Fayetteville, GA
Click here to add this to my saved trials
Garfield Heights, Ohio 44125
?
mi
from
Garfield Heights, OH
Click here to add this to my saved trials
Little Rock, Arkansas 72211
?
mi
from
Little Rock, AR
Click here to add this to my saved trials
Oklahoma City, Oklahoma 73116
?
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Orange City, Florida 32763
?
mi
from
Orange City, FL
Click here to add this to my saved trials
Orlando, Florida 32803
?
mi
from
Orlando, FL
Click here to add this to my saved trials
Palmetto Bay, Florida
?
mi
from
Palmetto Bay, FL
Click here to add this to my saved trials
Rochester, New York 14618
?
mi
from
Rochester, NY
Click here to add this to my saved trials
?
mi
from
Smyrna, GA
Click here to add this to my saved trials
The Woodlands, Texas 77381
?
mi
from
The Woodlands, TX
Click here to add this to my saved trials
Wildomar, California 92595
?
mi
from
Wildomar, CA
Click here to add this to my saved trials